1. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
- Author
-
Minenkova O, Vesci L, De Santis R, Santapaola D, Cincinelli R, Musso L, Dallavalle S, and Giannini G
- Subjects
- Animals, Antineoplastic Agents chemical synthesis, Antineoplastic Agents metabolism, Avidin metabolism, Biotin chemical synthesis, Biotin metabolism, Camptothecin chemical synthesis, Camptothecin metabolism, Camptothecin therapeutic use, Cell Line, Tumor, Cell Proliferation drug effects, Female, Humans, Mice, Protein Binding, Antineoplastic Agents therapeutic use, Biotin analogs & derivatives, Biotin therapeutic use, Camptothecin analogs & derivatives, Carcinoma drug therapy, Ovarian Neoplasms drug therapy
- Abstract
Oxidized form of avidin, named AvidinOX, provides stable fixation of biotinylated molecules in tissues thus representing a breakthrough in topical treatment of cancer. AvidinOX proved to be a stable receptor for radiolabeled biotin, biotinylated antibodies and cells. In order to expand applicability of the AvidinOX-based delivery platform, in the present study we investigated the possibility to hold biotinylated chemotherapeutics in AvidinOX-treated sites. A novel biotinylated gimatecan-derived camptothecin, coded ST8161AA1, was injected at suboptimal doses into human tumors xenografted in mice alone or pre-complexed to AvidinOX. Significantly higher growth inhibition was observed when the drug was anchored to AvidinOX suggesting the potential utility of this delivery modality for the local treatment of inoperable tumors., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF